Zeng G, Wu Q, Pan H, Li M, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis 2021 Dec 7. pii: S1473-3099(21)00681.
PMID: 34890537